• News
  • SAN DIEGO
  • Medical

Quidel gains FDA approval for strep test

Quidel Corp. (Nasdaq: QDEL), a San Diego-based provider of rapid diagnostic testing solutions, reports it has received clearance from the Food and Drug Administration (FDA) to market its Lyra Direct Strep Assay.

This new molecular test detects and differentiates between pyogenic Group A and pyogenic C or G Streptococcal throat infections.

The assay kit includes an extraction-free, three-step sample preparation process that does not require automated extraction. This fast and easy direct-to-amplification procedure allows the assay to generate a result in just over an hour.

User Response
0 UserComments

Quidel Corp.

Company Website

10165 McKellar Ct.
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
QDEL
18.31
  -0.19  
- 1.03%
218,220,000
29.38
17.7

Insider Trade Data

Date Insider Shares Type Value
08/20/2015 Tamerius, John D 11,000 Exchange $134,530
08/20/2015 Tamerius, John D 11,000 Exchange $134,530
07/31/2015 Tamerius, John D 6,409 Exchange $80,946
07/31/2015 Tamerius, John D 6,409 Sell $134,861
07/31/2015 Tamerius, John D 6,409 Sell $134,861

Quidel Corp. Executive(s):

Douglas Bryant

  • Chief Executive Officer, President

Randall Steward

  • Chief Financial Officer

Similar Companies

NAICS - 325413 - In-Vitro Diagnostic Substance Manufacturing